Omeros (NASDAQ:OMER) Stock Price Down 5.4%

Omeros Co. (NASDAQ:OMER)’s stock price fell 5.4% on Friday . The stock traded as low as $14.58 and last traded at $14.65, 679,741 shares changed hands during mid-day trading. An increase of 29% from the average session volume of 525,576 shares. The stock had previously closed at $15.49.

Several research firms have recently weighed in on OMER. Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $71.00 price objective on shares of ExlService in a research note on Monday, May 6th. ValuEngine lowered shares of Yirendai from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 26th. HC Wainwright set a $55.00 price objective on shares of Acer Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $25.80.

The firm has a market cap of $718.70 million, a price-to-earnings ratio of -6.60 and a beta of 3.04. The stock’s 50 day simple moving average is $16.10.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million for the quarter, compared to analyst estimates of $23.18 million. The company’s quarterly revenue was up 1271.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.62) EPS. As a group, analysts predict that Omeros Co. will post -1.68 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in OMER. Advisory Services Network LLC bought a new stake in Omeros during the 1st quarter valued at $69,000. Legal & General Group Plc increased its stake in Omeros by 12.7% during the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 945 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Omeros by 16,167.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 9,862 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its stake in shares of Omeros by 417.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 12,911 shares in the last quarter. Finally, MML Investors Services LLC bought a new stake in shares of Omeros in the 4th quarter worth $217,000. Institutional investors and hedge funds own 52.12% of the company’s stock.

About Omeros (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: Dividend

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.